Barrett’s Esophagus

  • R. E. Sampliner


Intestinal Metaplasia Esophageal Adenocarcinoma High Grade Dysplasia GERD Symptom Argon Plasma Coagulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Sampliner RE (2002) Practice Parameters Committee ACG. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 97: 1888–1895PubMedCrossRefGoogle Scholar
  2. [2]
    Blot W, Devesa SS, Kneller RW, Fraumeni JF (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265(10): 1287–1289PubMedCrossRefGoogle Scholar
  3. [3]
    Brown LM, Devesa SS (2002) Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 11: 235–256PubMedCrossRefGoogle Scholar
  4. [4]
    Boyce HW (2000) Endoscopic definitions of esophagogastric junction regional anatomy. Gastrintest Endosc 51(5): 586–592CrossRefGoogle Scholar
  5. [5]
    Cameron AJ (2002) Epidemiology of Barrett’s esophagus and adenocarcinoma. Dis Esophagus 15: 106–108PubMedCrossRefGoogle Scholar
  6. [6]
    Gerson LB, Sheltler K, Triadafilopoloulos G (2002) Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 123: 461–467PubMedCrossRefGoogle Scholar
  7. [7]
    Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RKH, Vasudeva RS et al (2003) Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125: 1670–1677PubMedCrossRefGoogle Scholar
  8. [8]
    Drewitz DJ, Sampliner RE, Garewal HS (1997) The incidence of adenocarcinoma in Barrett’s esophagus — a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92(2): 212–215PubMedGoogle Scholar
  9. [9]
    Shaheen NJ, Crosby MA, Bozymski EM (2000) Is there publication bias in the reporting of cancer risk of Barrett’s esophagus? Gastroenterology 119: 333–338PubMedCrossRefGoogle Scholar
  10. [10]
    Anderson LA, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston BT, Watson RGP et al (2003) Mortality in Barrett’s oesophagus: results from a population based study. Gut 52: 1081–1084PubMedCrossRefGoogle Scholar
  11. [11]
    Conio M, Blanchi S, Lapertosa G, Ferraris R, Sablich R, Marchi S et al (2003) Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 98: 1931–1939PubMedCrossRefGoogle Scholar
  12. [12]
    Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM (2002) Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology: 26–33Google Scholar
  13. [13]
    Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340(11): 825–831PubMedCrossRefGoogle Scholar
  14. [14]
    Lieberman DA, Oehlke M, Helfand M, G.O.R.E. (1997) Risk factors for Barrett’s esophagus in community-based practice. Am J Gastroenterol 92(8): 1293–1297PubMedGoogle Scholar
  15. [15]
    Eisen GM, Sandier IS, Murray S, Gottfried M (1997) The relationship between gastroesophageal reflux disease and its complications with Barrett’s esophagus. Am J Gastroenterol 92: 27–31PubMedGoogle Scholar
  16. [16]
    Breslin NP, Thompson ABR, Bailey RJ, Blustein PK, Meddings J, Lalor E et al (2000) Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 46: 93–97PubMedCrossRefGoogle Scholar
  17. [17]
    Cameron AJ, Lomboy CT (1992) Barrett’s esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 103: 1241–1245PubMedGoogle Scholar
  18. [18]
    Soni A, Sampliner RE, Sonnenberg A (2000) Screening for high grade dysplasia in gastroesophageal reflux disease: is it cost effective? Am J Gastroenterol 95: 2086–2093PubMedCrossRefGoogle Scholar
  19. [19]
    Robertson CS, Mayberry JF, Nicholson DA, James P, Atkinson M (1988) Value of endoscopic surveillance in the detection of neoplastic change in Barrett’s oesophagus. Br J Surg 75: 760–763PubMedGoogle Scholar
  20. [20]
    Miros M, Kerlin MM, Walker N (1991) Only patients with dysplasia progress to adenocarcinoma in Barrett’s oesophagus. Gut 32: 1441–1446PubMedGoogle Scholar
  21. [21]
    Reid B, Levine D, Longton G, Blount P, Rabinovitch P (2000) Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low and high risk patient subsets. Am J Gastroenterol 95: 1669–1676PubMedGoogle Scholar
  22. [22]
    Weston AP, Badr AS, Hassanein RS (1999) Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett’s multifocal high grade dysplasia or adenocarcinoma. Am J Gastroenterol 94(12): 3413–3419PubMedCrossRefGoogle Scholar
  23. [23]
    Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O’Connell S et al (2001) Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 120: 1607–1619PubMedCrossRefGoogle Scholar
  24. [24]
    O’Connor JB, Falk GW, Richter JE (1999) The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus. Am J Gastroenterol 94(8): 2037–2042PubMedGoogle Scholar
  25. [25]
    Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ et al (2001) Secular trends in the epidemiology and outcome of Barrett’s oesophagus in Olmsted County, Minnesota. Gut 48: 304–309PubMedCrossRefGoogle Scholar
  26. [26]
    Streitz JM, Andrews CW, Ellis FH (1993) Endoscopic surveillance of Barrett’s esophagus: does it help? J Thorac Cardiovasc Surg 105: 383–388PubMedGoogle Scholar
  27. [27]
    Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR (1994) Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 108: 813–822PubMedGoogle Scholar
  28. [28]
    Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA (2002) Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology 122: 633–640PubMedCrossRefGoogle Scholar
  29. [29]
    Cooper GS, Yuan Z, Chak A, Rimm AA (2002) Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer 95: 32–38PubMedCrossRefGoogle Scholar
  30. [30]
    Fass R, Sampliner RE, Malagon IB, Hayden CW, Camargo L, Wendel CS et al (2000) Failure of oesophageal acid control in candidates for Barrett’s oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol 14: 597–602CrossRefGoogle Scholar
  31. [31]
    Sharma P, Weston A, Keeton S, Camargo L, Sampliner RE (2001) Control of esophageal acid exposure in patients with Barrett’s esophagus on rabeprazole. Am J Gastroenterol 96: S36(110)Google Scholar
  32. [32]
    Holscher AH, Bollschweiler E, Schneider PM, Siewert JR (1997) Early adenocarcinoma in Barrett’s oesophagus. Br J Surg 84: 1470–1473PubMedCrossRefGoogle Scholar
  33. [33]
    Ruol A, Merigliano S, Baldan N, Santi S, Petrin GF, Bonavina L et al (1997) Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophagogastric junction. Comparison between early cancer in Barrett’s esophagus (type I) and early cancer of the cardia (type II). Dis Esophagus 10: 190–195PubMedGoogle Scholar
  34. [34]
    Stein HJ, Feith M, Mueller J, Werner M, Siewert JR (2000) Limited resection of early adenocarcinoma in Barrett’s esophagus. Ann Surg 6: 733–742CrossRefGoogle Scholar
  35. [35]
    Begg CB, Cramer LD, Hoskins WJ, Brennan MF (1998) Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280: 1747–1751PubMedCrossRefGoogle Scholar
  36. [36]
    Birkmeyer JD, Siewers AE, Finlayson EVA, Stukel TA, Lucas FL, Batista I et al (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346: 1128–1137PubMedCrossRefGoogle Scholar
  37. [37]
    Hofstetter WL, Peters JH, DeMeester T, Hagen JA, DeMeester SR, Crookes PF et al (2001) Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg 234: 532–539PubMedCrossRefGoogle Scholar
  38. [38]
    Corey KE, Schmitz SM, Shaheen NJ (2003) Does a surgical anti-reflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol 98(11): 2390–2394PubMedCrossRefGoogle Scholar
  39. [39]
    Parilla P, Martinez de Haro L, Ortiz A, Munitiz V, Molina JB, Bermejo J et al (2003) Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 237(1): 291–298CrossRefGoogle Scholar
  40. [40]
    Csendes A (2004) Surgical treatment of Barrett’s esophagus: 1980–2003. World J Surg 28: 225–231PubMedCrossRefGoogle Scholar
  41. [41]
    Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G et al (2000) Endoscopic mucosal resection of early cancer and high grade dysplasia in Barrett’s esophagus. Gastroenterology 118: 670–677PubMedCrossRefGoogle Scholar
  42. [42]
    May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G et al (2002) Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Heptaol 14: 1085–1091CrossRefGoogle Scholar
  43. [43]
    Overholt B, Lightdale C, Wang K, Canto M, Burdick S, Barr H et al (2003) International, multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE): results of 24-month follow-up. Gastroenterology 124: A20CrossRefGoogle Scholar
  44. [44]
    Overholt BF, Panjehpour M, Halberg DL (2003) Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early carcinoma: long-term results. Gastrointest Endosc 58: 183–188PubMedCrossRefGoogle Scholar
  45. [45]
    Attwood SEA, Lewis CJ, Caplin S, Hemming K, Armstrong GRA (2003) Argon plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol 1: 258–263PubMedCrossRefGoogle Scholar
  46. [46]
    Gossner L, Stolte M, Sroka R, Rick K, May A, Hahg EG et al (1998) Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology 114: 448–455PubMedCrossRefGoogle Scholar
  47. [47]
    Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Filijou JF (2004) Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorin for intramucosal adenocarcinoma and high-grade dysplasia in Barrett’s esophagus. Gastrintest Endosc 59(7): 880–889CrossRefGoogle Scholar
  48. [48]
    Buttar NS, Wang KK, Burgart LJ, Song LMMWK, Lutzke LS, Wandersee SM et al (2003) Endoscopic appearance and extent of high-grade dysplasia in Barrett’s esophagus can predict the presence of cancer at esophagectomy. Am J Gastroenterol 98(9 Suppl): S28(81)Google Scholar
  49. [49]
    Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Theisen J, Peters JH et al (1999) Occult esophageal adenocarcinoma. Extent of disease and implications for effective therapy. Ann Surg 230: 433–440PubMedCrossRefGoogle Scholar
  50. [50]
    Tseng EE, Wu TT, Yeo CF, Heitmiller RF (2003) Barrett’s esophagus with high grade dysplasia: surgical results and long-term outcome — an update. J Gastrointest Surg 7: 164–171PubMedCrossRefGoogle Scholar
  51. [51]
    Garcia RT, Cello JP, Nguyen MH, Rogers SJ, Rodas A, Trinh HN et al (2003) Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial. Gastroenterology 125: 1606–1612PubMedCrossRefGoogle Scholar
  52. [52]
    Inadomi JM, Sampliner RE, Lagergren J, Lieberman D, Fendrick M, Vakil N (2003) Screening and surveillance for Barrett’s esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138(3): 176–186PubMedGoogle Scholar
  53. [53]
    Reid B, Prevo L, Galipeau P, Sanchez CA, Longton G, Levine D et al (2001) Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96: 2839–2848PubMedCrossRefGoogle Scholar
  54. [54]
    Shirvani VN, Ouatu-Lascar R, Kaur B, Omary B, Triadafilopoloulos G (2000) Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 118: 487–496PubMedCrossRefGoogle Scholar
  55. [55]
    Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA et al (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology 122: 1101–1112PubMedCrossRefGoogle Scholar
  56. [56]
    Corley DA, Kerlikowske K, Verma R, Buffler PA (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124: 47–56PubMedCrossRefGoogle Scholar
  57. [57]
    Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC (2004) Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 180(8): 387–391PubMedGoogle Scholar
  58. [58]
    El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE (2004) Proton pump inhibitors are associated with reduced incidence of dysplasia. Am J Gastroenterol (in press)Google Scholar

Copyright information

© Springer-Verlag/Wien 2006

Authors and Affiliations

  • R. E. Sampliner
    • 1
  1. 1.Arizona Health Sciences CenterSouthern Arizona VA Health Care SystemTucsonUSA

Personalised recommendations